

Quantitative determination of ALAT (GPT) in Serum or Plasma. Kinetic UV method IFCC optimized.

**REF** CC1224 R1: 3x20 mL R2: 1x15 mL



**REF** CC1222 R1: 3x40 mL R2: 1x30mL

**REF** CC1220 R1: 3x80 mL R2: 1x60 mL

## METHOD AND PRINCIPLE

Optimized Kinetic UV-test according to IFCC (International Federation of Clinical Chemistry and Laboratory Medicine).

GPT/ALAT catalyzes the transformation of 2-Oxoglutarate and L-Alanine into L-Glutamate and Pyruvate. Subsequently, the Lactate Dehydrogenase (LDH) catalyzes the transformation of the pyruvate formed and of the NADH into L-Lactate and NAD<sup>+</sup> producing a decrease in Absorbance (Abs) of the reaction which is measured photometrically at a wavelength of 340 nm. The rate of decrease of the Abs is proportional to the activity of the enzyme GPT/ALAT in the sample.



## CLINICAL SIGNIFICANCE

The group of enzymes called transaminase exist in tissues of many organs. Necrotic activity in these organs causes a release of abnormal quantities of enzyme into the blood where they are measured. Since heart tissue is rich in GOT increased serum levels appear in patients after myocardial infarction, as well as in patients with muscle disease, muscular dystrophy and dermatomyositis. The liver is specially rich in GPT, being the enzyme measurement used primarily as a test for infectious and toxic hepatitis, although high levels of both GPT and GOT may also be found in cases of liver cell damage and acute pancreatitis, suggesting that the obstruction of the biliary tree by the edematous pancreas and the presence of associate hepatic disease may contribute to elevated GOT levels in these patients. Slight or moderate elevations of GOT and GPT activities may be observed after intake of alcohol and after administration of various drugs, such as salicylates, opiates and ampicillin.

## REAGENT COMPOSITION

### Reagent (R1)

TRIS, pH 7.65	100 mmol/L
L-Alanine	500 mmol/L
LDH (lactatedehydrogenase)	≥ 1700 U/L

### Reagent (R2)

2-Oxoglutarate	15 mmol/L
NADH	0.18 mmol/L

## REAGENT PREPARATION AND STABILITY

Liquid and ready to use reagents, stable until the expiry date shown, if stored as indicated on the label and avoid contamination, evaporation and prolonged exposure to direct light.

Do not freeze the reagents.

Discard the reagents if signs of deterioration appear, such as the presence of particles and turbidity or failure to recover the values of certified control sera or Blank Absorbance (Abs) of Working Reagent at 340 nm < 1.000 in 1 cm cuvette.

After opening the bottles, it is advisable to withdraw the necessary volume, to immediately close the bottles and store them in the fridge in order to avoid contamination, degradation from direct light and evaporation.

For the Sample Starter Procedure, prepare a Work Solution by mixing 4 parts of R1 and 1 part of R2 (E.g. 20 mL of R1 + 5 mL of R2). Stability: Stability: 5 days at 15-25 ° C, 30 days at 2-8 ° C.

For the Substrate Starter Procedure, reagents R1 and R2 are ready to use and stable until the expiry date if stored at the temperature shown on the label and avoid contamination, prolonged exposure to direct light and evaporation.

## SPECIMEN

Serum, heparin plasma or EDTA plasma. Avoid hemolysate or lipemic samples. Separate the serum from the clot quickly.

Loss of activity within 3 days: at 2° - 8 ° C < 8 %; at 15° - 25 ° C < 10 %.

Stability: 8 hours at 20-25° C, 5 days at 2-8° C, 3 months at -20 ° C.

Discard contaminated specimens.

## PROCEDURE

Wavelength:	340 nm
Temperature:	37°C
Measurement:	against distilled water

### Sample Start procedure:

Working Reagent	1000 µL
Sample	100 µL

Mix, read Absorbance (Abs) after 1 minute and start stopwatch. Read Absorbance again after 1, 2 and 3 minutes.

Calculate  $\Delta\text{Abs}/\text{min}$  (average).

### Substrate Start procedure:

Reagent (R1)	800 µL
Sample	100 µL

Mix and after 1 minute add reagent (R2):

Reagent (R2)	200 µL
--------------	--------

Mix, read Absorbance (Abs) after 1 minute and start stopwatch. Read Absorbance again after 1, 2 and 3 minutes.

Calculate  $\Delta\text{Abs}/\text{min}$  (average).

## CALCULATION

Calculation Factor (reading at 340 nm in 1 cm cuvette):

$$\text{GPT-ALAT (U/L)} = \Delta\text{Abs}/\text{min} \times 1746$$

### Multiparametric Calibrator:

Calculate a specific factor using a certificate multiparametric calibrator:

$$\text{GPT-ALAT (U/L)} = \Delta\text{Abs}/\text{min} \times \text{Factor}$$

$$\text{Factor} = \frac{\text{Calibrator Concentration}}{\Delta\text{Abs}/\text{min (average)}}$$

Conversion Factor: U/L x 0.0167 = µKat/L = µmol/sec/L

## CALIBRATION

The results depend on the accuracy of the calibration, on the correct setting of the test on the instrument, on the correct volumetric ratio of reagent / sample and on the correct analysis temperature.

Use **MTD Diagnostics Calibrator**:

**Chemistry Multicalibrator - REF CAL1010 (10 x 3 mL)**

## QUALITY CONTROL

Normal and abnormal control sera of known enzymatic activity should be analysed routinely with each group of unknown samples utilizing **MTD Diagnostics Quality Control Material**:

**Chemistry Control N - REF CNN1010** 10 x 5 mL (Level 1)

**Chemistry Control P - REF CNP1020** 10 x 5 mL (Level 2)

## EXPECTED VALUES

Women < 31 U/L

Men < 41 U/L

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference range. For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

## PERFORMANCE

### PRECISION:

Low Level: Samples = 20; Average = 45; S.D. = 0.92; CV = 2.04%

High Level: Samples = 20; Average = 183; S.D. = 2.16; CV = 1.18%

**ACCURACY (CORRELATION):** A comparison between this method (x) and a certified method of trade (y) gave the following correlation:

$$y = 1.003 x + 0.0998 \quad r = 0.997.$$

**SENSITIVITY:** 2 U/L

**LINEARITY:** 2 - 280 U/L

## SPECIFICITY / INTERFERENCES

No interference was observed by Bilirubin up to 20 mg/dL, Haemoglobin up to 500 mg/dL and Lipemia up to 1000 mg/dL Triglycerides.

## NOTES

1. This method may be used with different instruments. Any application to an instrument should be validated to demonstrate that results meet the performance characteristics of the method. It is recommended to validate periodically the instrument. Contact your distributor for any question on the application method.

2. Clinical diagnosis should not be made on findings of a single test result, but should integrate both clinical and laboratory data.

## PRECAUTIONS

The product does not contain any other hazardous substances or mixtures according to EC Regulation No. 1272/2008 (CLP) or their concentrations are such that they are not considered to be persistent, bioaccumulative or toxic (PBT). Therefore, it is not subject to the special labeling required by the aforementioned regulation. The product is labeled according to the directive for CE marking (98/79 / EC). Sodium Azide less than 0.1%.

However, in compliance with the normal prudential rules that everyone has to keep managing any chemical or laboratory reagent, in case of contact of reagents with the operator, you must apply the following first aid:

S26 (P305 – P351 – P338): In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

S28 (P302 – P352): After contact with skin, wash immediately with plenty of water.

S36/37/39 (P280): Wear suitable protective clothing, gloves and eye/face protection.

S46 (P301 – P310): If swallowed, seek medical advice immediately and show container or label. If victim is conscious and alert, wash out mouth with water.

S56 (P273): Dispose of this material and its container at hazardous or special waste collection point.

S63 (P304 – P340): In case of accident by inhalation: remove casualty to fresh air and keep at rest. If breathing is difficult, give oxygen and get medical aid.

All samples, calibrators and controls should be treated as potentially infectious material capable of transmitting HIV and hepatitis

FOR MORE INFORMATION, REQUEST SAFETY DATA SHEET FOR REAGENT (MSDS) AT THE MANUFACTURER.

## SIMBOLOGY

	CE Mark (EC Directive 98/79)		
	In Vitro Diagnostic		Temperature Limitation
	Consult instructions for use		Contains sufficient for <n> test
	Catalog Number		Use By
	Batch Code		Manufacturer

## BIBLIOGRAPHY

Moss DW, Henderson AR. Clinical enzymology. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: W.B Saunders Company; 1999. p. 617-721.

Schumann G, Bonora R, Ceriotti F, Féraud G et al. IFCC primary reference procedure for the measurement of catalytic activity concentrations of enzymes at 37 °C. Part 5: Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase. ClinChem Lab Med 2002;40:725-33

Thomas L. Alanine aminotransferase (ALT), Aspartate aminotransferase (AST). In: Thomas L, editor. Clinical Laboratory Diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft; 1998. p. 55-65.